GlassScriptPhysician profile
David Voog Tobin
NPI 1992496921
$5,229.26
in general payments reported to CMS, 2019-2025
22 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,080 · 2024: $2,540 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,189.74 | 2023-2025 | Caplyta |
| Abbvie INC. | $733.63 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $628.45 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $432.90 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $374.40 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $327.99 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $284.16 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $204.17 | 2023-2024 | Trintellix |
| Corium, LLC | $178.97 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $143.00 | 2024 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $127.20 | 2024-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $103.10 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $88.33 | 2024-2025 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $87.61 | 2024-2025 | Qelbree |
| Tris Pharma INC | $82.02 | 2023-2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $69.75 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $56.30 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $32.99 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $32.25 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.30 | 2025 | Abilify Maintena |
| Luye Pharma (USA) LTD. | $16.55 | 2025 | Erzofri Extended-Release |
| Almatica Pharma LLC | $16.45 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.